Lorcaserin (Belviq) Withdrawn From US Market Due to Cancer Risk

biotech healthcare

The FDA is not recommending special cancer screenings for patients who have taken lorcaserin. The action follows an FDA alert in January about a possible elevated cancer risk based on its preliminary analysis of the study. Patients were also advised Feb. 13 to stop taking the drug and talk to their providers about alternative weight-loss medications and weight-management programs. They were also told to dispose of the pills at a drug take-back location if available, but if not, to mix them with an "unappealing substance" such as dirt, cat litter, or used coffee grounds; seal them in plastic bag; and put them in the trash. This article originally appeared on MDedge.com . Cite this: Lorcaserin (Belviq ) Withdrawn From US Market Due to Cancer Risk - Medscape - Feb 13, 2020.